PPARA and hyperlipidemia: Fenofibrate, a PPAR-α agonist, is commonly used for hyperlipidemia treatment and has demonstrated potential anticancer effects, as it influences apoptosis, cell-cycle arrest, invasion, and migration in various cancer cell lines, including those of breast, liver, glioma, prostate, pancreas, and lung cancer (Lian et al., 2018).